Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation

NCT07729332 on ClinicalTrials.gov · last registry update 2026-07-27

Registered but not yet open, with 60 participants planned. Due to report 31 July 2031, alongside 3 other tracked readouts that quarter. Primary outcome, as filed: Percent change in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: orforglipron
Foundayo
Sponsor: Massachusetts General Hospital
Sponsor type: Other
Enrollment: 60
Started: 2026-11-01
Primary completion: 2031-07-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent change in body weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.